Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracy Reed

Podiatrist Saint Louis, MO Doctor of Podiatric Medicine

NPI 1871593178 CMS profile 357726

11125 Dunn Road Suite 301, Saint Louis, MO 63195

Open in the dashboard

General payments

$8,140

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tracy Reed of Saint Louis, MO is reported in the CMS Open Payments database as having received $8,140 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,096 19
2024 General $1,506 32
2023 General $2,815 54
2022 General $1,694 15
2021 General $235 15
2020 General $30 2
2019 General $765 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracy Reed
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Tracy Reed were reported at $1,096. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Tracy Reed Podiatrist median Middle half National median
2019 $765 $196 $72–$601 $163
2020 $30 $118 $38–$335 $114
2021 $235 $169 $57–$573 $132
2022 $1,694 $220 $74–$782 $149
2023 $2,815 $208 $71–$635 $160
2024 $1,506 $237 $87–$681 $164
2025 $1,096 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $2,316 32 payments
  2. Treace Medical Concepts, Inc. $1,168 10 payments
  3. Kerecis Limited $1,166 15 payments
  4. Organogenesis Inc. $801 26 payments
  5. Averitas Pharma Inc. $549 12 payments
  6. Smith+Nephew, Inc. $401 24 payments
  7. Paratek Pharmaceuticals, Inc. $239 18 payments
  8. Next Science LLC $225 8 payments
  9. ProgenaCare Global, LLC $209 3 payments
  10. Triad Life Sciences Inc. $169 1 payment
  11. Other $897 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,483 159 payments
  2. Travel and Lodging $1,656 7 payments
Products named General payments · program years 2019–2025
  1. Senza $2,237 28 payments
  2. LAPIPLASTY SYSTEM $1,149 9 payments
  3. Kerecis SurgiClose Wound Care $609 11 payments
  4. Kerecis GraftGuide $609 11 payments
  5. Kerecis SurgiClose Wound Care $609 11 payments
  6. Kerecis SurgiClose Wound Care $609 11 payments
  7. Kerecis SurgiClose Wound Care $609 11 payments
  8. Kerecis Omega3 SurgiClose $556 4 payments
  9. Kerecis Omega3 Marigen Wound Care $556 4 payments
  10. Kerecis Omega3 Marigen Wound Care $556 4 payments
  11. Other $4,534 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,161

Median for Podiatry: 160

Drug cost

$49,495

Median for Podiatry: $2,368

Branded share of claims

61.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Ciclopirox Olamine Brand 649 $26,764
Santyl Collagenase Clostridium Hist. Brand 14 $9,480
Griseofulvin Ultramicrosize Generic 37 $5,320
Clotrimazole Generic 81 $2,224
Ciclopirox Generic 34 $1,059
Terbinafine Hcl Generic 129 $939
Triamcinolone Acetonide Generic 59 $822
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $816
Ammonium Lactate Generic 36 $625
Ketoconazole Generic 22 $527

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record